Health · 9 views
Novel Drug Doubles PFS in Heavily Pretreated, HR-Positive Breast Cancer
(MedPage Today) -- Patients with heavily pretreated hormone receptor (HR)-positive breast cancer lived twice as long without disease progression with the novel antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), a randomized…
Summary
(MedPage Today) -- Patients with heavily pretreated hormone receptor (HR)-positive breast cancer lived twice as long without disease progression with the novel antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), a randomized trial
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- ‘What’s the safest way to defrost chicken?’ We’re answering your food safety questionsContinue reading
- Black patients can face longer breast cancer care delays, study findsContinue reading
- Baby Aspirin Misses Mark for Primary Cardiovascular Prevention in CKDContinue reading
- GLP-1s May Interact With Psychiatry MedicationContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow